Table 4.
Comparison of the incidence of adverse events between the groups.
| Parameter | Cinobufacini group (n = 31) | Epirubicin group (n = 25) | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | Grade 1 | Grade 2 | Grade 3 | Total | Grade 1 | Grade 2 | Grade 3 | |
| Liver function | ||||||||
| TB | 18 (58.0) | 13 (41.9) | 5 (16.1) | 0 (0.0) | 21 (84.0) | 4 (16.0) | 15 (60.0) | 2 (8.0) |
| ALT | 16 (51.7) | 8 (25.8) | 6 (19.4) | 2 (6.5) | 22 (88.0) | 6 (24.0) | 11 (44.0) | 5 (20.0) |
| AST | 18 (58.1) | 9 (29.0) | 6 (19.4) | 3 (9.7) | 20 (80.0) | 11 (44.0) | 6 (24.0) | 3 (12.0) |
| Hematologic system | ||||||||
| WBC | 1 (3.2) | 1 (3.2) | 0 (0.0) | 0 | 8 (32.0) | 6 (24.0) | 2 (8.0) | 0 |
| HGB | 6 (19.3) | 5 (16.1) | 1 (3.2) | 0 | 5 (20.0) | 5 (20.0) | 0 | 0 |
| PLT | 5 (16.1) | 4 (12.9) | 1 (3.2) | 0 | 14 (56.0) | 9 (36.0) | 2 (8.0) | 3 (12.0) |
| Clinical symptom | ||||||||
| Fever | 14 (45.2) | — | — | — | 17 (68.0) | — | — | — |
| Liver pain | 7 (22.6) | — | — | — | 20 (80.0) | — | — | — |
| Abdominal distension | 5 (16.1) | — | — | — | 13 (52.0) | — | — | — |
| Nausea and vomiting | 0 (0.0) | — | — | — | 9 (36.0) | — | — | — |
TB: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; WBC: white blood cells; HGB: hemoglobin; PLT: platelets.